A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):335-7. doi: 10.1097/QAI.0b013e3181938fc9.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • CD4 Lymphocyte Count
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Lamivudine / administration & dosage
  • Lamivudine / therapeutic use
  • Lopinavir
  • Male
  • Nevirapine / administration & dosage
  • Nevirapine / therapeutic use
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / therapeutic use
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Ritonavir / administration & dosage
  • Ritonavir / therapeutic use
  • Viral Load
  • Zidovudine / administration & dosage
  • Zidovudine / therapeutic use

Substances

  • HIV Protease Inhibitors
  • Pyrimidinones
  • Reverse Transcriptase Inhibitors
  • Lopinavir
  • Lamivudine
  • Zidovudine
  • Nevirapine
  • Ritonavir